Pausing the HIV deal makes sense in case they’ve been

New Post Public Reply Private Reply Replies (1) Message Board
Fortuno Watching_CYDY #12289
449
Pausing the HIV deal makes sense in case they’ve been approached for a BO.
Any party interested in taking Cydy over would not like the existence of a HIV licensing agreement for a product that could be a treatment for many other and different diseases. Makes things far too complicated. Better buy without such a licensing agreement being closed.

Could be other (even more benificial) deals are in play too, then a pause would make sense.

NP did say he could sign the HIV deal now. So it’s upto Cydy to close it or not. It seems like it’s not in the hands of our potential partner or that the potential partner walked away.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 165

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 58

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 153

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 148

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 239

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 247

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 211

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 89

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading

Top 5 Most Recently Viewed Articles

Tech Titans Rally: Stock Highlights You Can't Miss Today

Updated Category News Views 204

Market Overview Recent trading sessions in the U.S. saw mixed results. While the Dow Jones Industrial Average experienced a slight decline, the S&P 500 showed minimal movement. In contrast, the tech-centered Nasdaq showed a modest uptick as many companies presented their earnings. Federal Reserve Updates The Federal Reserve's decision to hold interest rates steady at...

Continue Reading
Investment Growth: Alphabet Stock's Journey Over Two Decades

Updated Category News Views 265

Understanding the Performance of Alphabet Stock Alphabet (NASDAQ: GOOGL) has consistently demonstrated remarkable growth, outpacing the market by an impressive 9.36% on an annualized basis. This translates to an average annual return of 18.3%, showcasing the company's ability to thrive even amid challenging economic conditions. With a market capitalization soaring to...

Continue Reading
Palantir Technologies Expands with 26 Partnerships in 15 Sectors

Updated Category News Views 885

Palantir's Remarkable Growth Journey Palantir Technologies Inc (NASDAQ: PLTR) has been making waves in the enterprise software landscape. In merely ten months, the company has successfully formed 26 partnerships across 15 different sectors, a feat that extends its reach well beyond its traditional defense-oriented image. This surge in collaboration indicates its...

Continue Reading
Bitcoin Market Dynamics Shift Amidst Emerging Trends

Updated Category News Views 148

Bitcoin Market Dynamics Shift Amidst Emerging Trends The financial markets are currently navigating through a phase of cautious optimism, with the leading indices showing modest gains. A notable exception to this trend is Bitcoin, which has recently displayed some volatility. After a significant breakout, Bitcoin encountered a sudden reverse, leading to concerns of a...

Continue Reading
Stifel Financial Corp. Announces Cash Dividends for Investors

Updated Category News Views 129

Stifel Financial Corporation's Dividend Announcement Stifel Financial Corp. announces a substantial cash dividend for its common stock shareholders, declaring a payout of $0.46 per share. This announcement comes as part of the company's regular financial strategy aimed at rewarding its shareholders. The payment is scheduled for September 16, with shareholders on record as...

Continue Reading